Biomarker Tests Market Research Report - Global Forecast till 2027

Global Biomarker Tests Market Research Report: Information by Application (Cancer, Cardiovascular, Infectious Diseases, Central Nervous System and others), End User (Pharma & Biotech Companies, Diagnostic Tool Companies, Healthcare IT/Big Data Companies and Clinical Laboratories) and Region (North America, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2027

ID: MRFR/LS/2428-CR | August, 2019 | Region : Global

Market Scenario:


Global Biomarker Tests Market accounted for USD 9,375 million in 2019 and is projected to reach USD 31859.73 Million by 2027 and register 14.60% CAGR during the forecast period. Biomarker testing, also known as molecular testing or genetic testing, is a set of tests that determines the molecular signs of health, which helps healthcare professionals in offering the best care for their patients. Most healthcare professionals adopt diagnosis tests to elucidate and support their clinical decision making. Some of the factors driving the market growth are increasing the involvement of patients in personal healthcare, mounting demand for biomarkers in other technologies such as next-generation sequencing technologies, ultra-high throughput sequencing, rising prevalence of genetic diseases, and growing potential for biomarkers in targeted therapies. Along with advances in healthcare, people are becoming more health or fitness conscious. Increasing inclination of people towards personalized healthcare is augmenting the market growth. Biomarker test services deal with cancer, cardiovascular diseases (CVDs), and infectious diseases and facilitate their treatment along with specific diagnostic tests and prevention methods are boosting the market growth.


On the contrary, lack of awareness about the possible applications of biomarkers, stringent regulatory framework, and lack of research and indications creating difficulties in their implementation are the factors anticipated to impede the market growth.


Market Dynamics


Growing potential for biomarkers in targeted therapies is fostering market growth. Recent advances in cancer care have been most closely associated with genomic medicine. Studying the genetic mutations of cancerous tumors helps physicians prescribe specific medication to fight particular cancer types. But there are only a few cancers that have been associated with specific genetic mutations. For some forms of breast cancer, doctors have years of experience in genomic analysis to determine the most appropriate treatments for their patients. Physicians use DNA testing to analyze the mutation of the BRCA gene in women with a family history of breast or ovarian cancer. Thus, with biomarkers playing a major role in the detection, diagnosis, and treatment of cancer, this factor is assisting in the market growth.

Global Biomarker Tests Market Size, by Application, 2019 (%)


  Biomarker Tests Market


Source: MRFR Analysis


Segmentation


The global biomarker tests market has been segmented into application and end user.


Based on application, the global market has been categorized into cancer, cardiovascular, infectious diseases, central nervous system, and others. Based on end user, the global market has been classified into pharma & biotech companies, diagnostic tool companies, healthcare IT/big data companies, and clinical laboratories.


By application, in 2019, the cancer segment dominated the market due to the growing cases of cancer and the increasing demand for rapid and accurate diagnostic tools and personalized medicines. For instance, according to the World Health Organization (WHO), in 2019, cancer was the second-leading cause of death worldwide and accounted for about 9.6 million deaths. Globally, in 2019, about 1 in 6 deaths were due to cancer.


Regional Analysis


Based on region, the global biomarker tests market is segmented into North America, Europe, Asia-Pacific, and the Middle East & Africa.


North America dominated the market in 2019 due to increasing disease burden, the presence of major market players, favorable government initiatives, and regulatory entities, and growing adoption of biomarker testing in the US and Canada. The presence of market players such as Pfizer Inc., Quest Diagnostics, Abbott, Thermo Fisher Scientific, Inc., and Bio-Rad Laboratories, Inc. is enabling the prompt product supply to the market, thereby contributing to the regional market growth.


Europe is expected to be the second-largest region in the market owing to the increasing cases of cardiovascular diseases, flourishing healthcare industries, and increasing technological advances in products. For instance, as per the data published by European Heart Network, every year, cardiovascular diseases cause 3.9 million deaths in Europe and more than 1.8 million deaths in the European Union (EU).


Asia-Pacific is expected to register the fastest CAGR over the forecast period due to the presence of prominent biomarker companies and increasing R&D investment in developing countries. In addition, the cost of clinical trials in developing countries is lower as compared to the developed countries, which is expected to support this profitable market growth during the assessment period.


The Middle East & Africa is expected to represent moderate market growth in the near future owing to growing awareness about biomarker testing, developing healthcare infrastructure, and increasing adoption of biomarker testing in the UAE, Saudi Arabia, and Egypt.


Key Players


The prominent players in the global biomarker tests market are F. Hoffmann-La Roche AG, Novartis AG, Pfizer Inc., GlaxoSmithKline plc, GE Healthcare, Medtronics plc, and Quest Diagnostics. The market participants have adopted several organic and inorganic growth strategies to gain a competitive advantage. These strategies include new product launches, mergers & acquisitions, partnerships and collaborations, and joint ventures (JVs) 


Key Updates



  • In May 2019, QIAGEN N.V. launched the first US Food and Drug Administration (FDA)-approved companion diagnostic for identifying breast cancer patients who may benefit from treatment with Novartis' Piqray (alpelisib), a PI3K inhibitor



  • In May 2017, Roche Diagnostics received the US FDA’s approval for biomarker assay to treat bladder cancer. This biomarker assay test evaluates the status of the patient programmed death-ligand 1 (PD-L1) by using both immune cell staining and tumor cell staining and scoring within the tumor.


Market Segmentation


Global Biomarker Tests Market, by Application



  • Cancer

  • Cardiovascular

  • Infectious Diseases

  • Central Nervous System

  • Others


Global Biomarker Tests Market, by End User



  • Pharma & Biotech Companies

  • Diagnostic tool companies

  • Healthcare IT/Big data companies

  • Clinical laboratories


Global Biomarker Tests Market, by Region



  • North America

    • US

    • Canada





  • Europe

    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Rest of Europe





  • Asia-Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Rest of Asia Pacific





  • Middle East & Africa

    • UAE

    • Saudi Arabia

    • Egypt

    • Rest of Middle East & Africa




Available Additional Customizations



  • Mega Trends in the Market

  • Additional Companies

    • Abbott

    • Epigenomics AG

    • Thermo Fisher Scientific, Inc.

    • Bio-Rad Laboratories, Inc.

    • QIAGEN N.V.




Intended Audience



  • Biomarker test devices manufacturers and vendors

  • Medical research laboratories

  • Pharmaceutical & biotechnology companies

  • Market research and consulting service providers

  • Potential investors

  • Government research institutes

  • Academic institutes and universities

1 Report Prologue

1.1 Introduction 10

1.2 FDA Regulations 11

2 Scope Of The Study

2.1 Introduction 13

2.2 Research Objective 13

2.3 Assumptions & Limitations 14

2.3.1 Assumptions 14

2.3.2 Limitations 14

2.4 Market Structure 14

3 Research Methodology

3.1 Primary Research 16

3.2 Secondary Research 16

4 Market Factor Analysis

4.1 Porters Five Forces 17

4.1.1 Bargaining Power Of Suppliers 18

4.1.2 Bargaining Power Of Buyer 18

4.1.3 Threat Of Substitutes 18

4.1.4 Threat Of New Entrants 19

4.1.5 Intensity Of Rivalry 19

4.2 Value Chain 19

4.2.1 Device Manufacturer & Drug Producers 20

4.2.2 Healthcare Providers 20

4.2.3 Healthcare ITs Or Big Data Companies 20

4.2.4 Regulators 20

4.2.5 Third Party Payers 20

4.2.6 Patients 20

5 Market Dynamics

5.1 Introduction 21

5.2 Drivers 21

5.2.1 Involvement Of Patients In Personal Healthcare 21

5.2.2 Demand For Biomarkers In Other Technologies Such As Next-Generation Sequencing Technologies And Ultra-High Throughput Sequencing. 21

5.2.3 Growing Prevalence Of Genetic Diseases 22

5.2.4 Growing Potential For Biomarkers In Targeted Therapies 22

5.3 Restrains 22

5.3.1 Lack Of Awareness About The Possible Applications Of Biomarkers 22

5.3.2 Regulatory Framework 22

5.3.3 Lack Of Research And Indications Creating Difficulties In The Application 23

5.4 Opportunities 24

5.4.1 Introduction Of Biomarkers In Developing Nations 24

6 Biomarker Test Market, By Applications

6.1 Cancer Application 26

6.2 Cardiovascular Application 26

6.3 Infectious Diseases Application 27

6.4 Central Nervous System Application 27

6.5 Others Applications 28

7 Biomarker Test Market, By End Users

7.1 Pharma & Biotech Companies 30

7.2 Diagnostic Tool Companies 30

7.3 Healthcare IT/Big Data Companies 31

7.4 Clinical Laboratories 31

8 Biomarker Test Market, By Regions

8.1 North America 33

Biomarker Test Market, By Applications

Biomarker Test Market, By End Users

Biomarker Test Market, By Regions

8.1.1 US 35

Biomarker Test Market, By Applications

Biomarker Test Market, By End Users

Biomarker Test Market, By Regions

8.1.2 Canada 36

Biomarker Test Market, By Applications

Biomarker Test Market, By End Users

Biomarker Test Market, By Regions

8.2 Europe 37

Biomarker Test Market, By Applications

Biomarker Test Market, By End Users

Biomarker Test Market, By Regions

8.2.1 Germany 39

Biomarker Test Market, By Applications

Biomarker Test Market, By End Users

Biomarker Test Market, By Regions

8.2.2 France 40

Biomarker Test Market, By Applications

Biomarker Test Market, By End Users

Biomarker Test Market, By Regions

8.2.3 UK 41

Biomarker Test Market, By Applications

Biomarker Test Market, By End Users

Biomarker Test Market, By Regions

8.2.4 Italy 42

Biomarker Test Market, By Applications

Biomarker Test Market, By End Users

Biomarker Test Market, By Regions

8.2.5 Spain 43

Biomarker Test Market, By Applications

Biomarker Test Market, By End Users

Biomarker Test Market, By Regions

8.2.6 Rest Of Europe 44

Biomarker Test Market, By Applications

Biomarker Test Market, By End Users

Biomarker Test Market, By Regions

8.3 Asia-Pacific 45

Biomarker Test Market, By Applications

Biomarker Test Market, By End Users

Biomarker Test Market, By Regions

8.3.1 Japan 47

Biomarker Test Market, By Applications

Biomarker Test Market, By End Users

Biomarker Test Market, By Regions

8.3.2 China 48

Biomarker Test Market, By Applications

Biomarker Test Market, By End Users

Biomarker Test Market, By Regions

8.3.3 India 49

Biomarker Test Market, By Applications

Biomarker Test Market, By End Users

Biomarker Test Market, By Regions

8.3.4 South Korea 50

Biomarker Test Market, By Applications

Biomarker Test Market, By End Users

Biomarker Test Market, By Regions

8.3.5 Australia 51

Biomarker Test Market, By Applications

Biomarker Test Market, By End Users

Biomarker Test Market, By Regions

8.3.6 Rest Of Asia-Pacific 52

Biomarker Test Market, By Applications

Biomarker Test Market, By End Users

Biomarker Test Market, By Regions

8.4 Middle East & Africa 53

Biomarker Test Market, By Applications

Biomarker Test Market, By End Users

Biomarker Test Market, By Regions

8.4.1 UAE 55

Biomarker Test Market, By Applications

Biomarker Test Market, By End Users

Biomarker Test Market, By Regions

8.4.2 Saudi Arabia 56

Biomarker Test Market, By Applications

Biomarker Test Market, By End Users

Biomarker Test Market, By Regions

8.4.3 Egypt 57

Biomarker Test Market, By Applications

Biomarker Test Market, By End Users

Biomarker Test Market, By Regions

8.4.4 Rest Of Middle & Africa 58

Biomarker Test Market, By Applications

Biomarker Test Market, By End Users

Biomarker Test Market, By Regions

9 Competitive Landscape

10 Company Profiles

10.1 F. Hoffmann-La Roche AG 60

10.1.1 Overview 60

10.1.2 Product/Business Segment Overview 60

10.1.3 Financial Updates 61

10.1.4 Key Developments 61

10.1.5 SWOT Analysis 62

10.2 Novartis AG 63

10.2.1 Overview 63

10.2.2 Product/Business Segment Overview 63

10.2.3 Financial Updates 64

10.2.4 Key Developments 65

10.2.5 SWOT Analysis 65

10.3 Pfizer Inc. 66

10.3.1 Overview 66

10.3.2 Product/Business Segment Overview 66

10.3.3 Financial Updates 66

10.3.4 Key Developments 67

10.3.5 SWOT Analysis 68

10.4 GlaxoSmithKline Plc. 69

10.4.1 Company Overview 69

10.4.2 Product Overview 69

10.4.3 Financial Overview 69

10.4.4 Key Developments 70

10.4.5 SWOT Analysis 71

10.5 GE Healthcare 72

10.5.1 Company Overview 72

10.5.2 Product/Business Segment Overview 72

10.5.3 Financial Overview 72

10.5.4 Key Developments 73

10.5.5 SWOT Analysis 74

10.6 Medtronics 75

10.6.1 Company Overview 75

10.6.2 Product/Business Segment Overview 75

10.6.3 Financial Overview 75

10.6.4 Key Developments 76

10.7 Quest Diagnostics 78

10.7.1 Company Overview 78


10.7.2 Product Overview 78

10.7.3 Financial Overview 78

10.7.4 Key Developments 79

11 List Of Tables

TABLE 1 CANCER BIOMARKERS FOR WHICH TESTING IS MANDATED BY THE FDA PRIOR TO USE OF THE DRUG 11

TABLE 2 GLOBAL BIOMARKER TESTS MARKET, BY APPLICATION (USD MILLION) (2020–2027) 25

TABLE 3 GLOBAL BIOMARKER TEST MARKET, BY CANCER APPLICATION (USD MILLION) (2020–2027) 26

TABLE 4 GLOBAL BIOMARKER TEST MARKET, BY CARDIOVASCULAR APPLICATION (USD MILLION) (2020–2027) 26

TABLE 5 GLOBAL BIOMARKER TEST MARKET, BY INFECTIOUS DISEASES APPLICATION (USD MILLION) (2020–2027) 27

TABLE 6 GLOBAL BIOMARKER TEST MARKET, BY CENTRAL NERVOUS SYSTEM APPLICATION (USD MILLION)

(2020–2027) 27

TABLE 7 GLOBAL BIOMARKER TEST MARKET, BY OTHERS APPLICATION (USD MILLION) (2020–2027) 28

TABLE 8 GLOBAL BIOMARKER TESTS MARKET, BY END USERS (USD MILLION) (2020–2027) 29

TABLE 9 GLOBAL BIOMARKER TEST MARKET, BY PHARMA & BIOTECH COMPANIES (USD MILLION) (2020–2027) 30

TABLE 10 GLOBAL BIOMARKER TEST MARKET, BY DIAGNOSTIC TOOL COMPANIES END USER (USD MILLION) (2020–2027) 30

TABLE 11 GLOBAL BIOMARKER TEST MARKET, BY HEALTHCARE IT/BIG DATA COMPANIES END USER (USD MILLION) (2020–2027) 31

TABLE 12 GLOBAL BIOMARKER TEST MARKET, BY CLINICAL LABORATORIES END USER (USD MILLION) (2020–2027) 31

TABLE 13 GLOBAL BIOMARKER TESTS MARKET, BY REGION (USD MILLION) (2020–2027) 32

TABLE 14 NORTH AMERICA BIOMARKER TESTS MARKET, BY COUNTRY (USD MILLION) (2020–2027) 33

TABLE 15 NORTH AMERICA BIOMARKER TESTS MARKET, BY APPLICATION (USD MILLION) (2020–2027) 34

TABLE 16 NORTH AMERICA BIOMARKER TESTS MARKET, BY END USERS (USD MILLION) (2020–2027) 34

TABLE 17 US BIOMARKER TESTS MARKET, BY APPLICATION (USD MILLION) (2020–2027) 35

TABLE 18 US BIOMARKER TESTS MARKET, BY END USERS (USD MILLION) (2020–2027) 35

TABLE 19 CANADA BIOMARKER TESTS MARKET, BY APPLICATION (USD MILLION) (2020–2027) 36

TABLE 20 CANADA BIOMARKER TESTS MARKET, BY END USERS (USD MILLION) (2020–2027) 36

TABLE 21 EUROPE BIOMARKER TESTS MARKET, BY COUNTRY (USD MILLION) (2020–2027) 37

TABLE 22 EUROPE BIOMARKER TESTS MARKET, BY APPLICATION BY APPLICATION (USD MILLION) (2020–2027) 38

TABLE 23 EUROPE BIOMARKER TESTS MARKET, BY END USERS (USD MILLION) (2020–2027) 38

TABLE 24 GERMANY BIOMARKER TESTS MARKET, BY APPLICATION BY APPLICATION (USD MILLION) (2020–2027) 39

TABLE 25 GERMANY BIOMARKER TESTS MARKET, BY END USERS (USD MILLION) (2020–2027) 39

TABLE 26 FRANCE BIOMARKER TESTS MARKET, BY APPLICATION BY APPLICATION (USD MILLION) (2020–2027) 40

TABLE 27 FRANCE BIOMARKER TESTS MARKET, BY END USERS (USD MILLION) (2020–2027) 40

TABLE 28 UK BIOMARKER TESTS MARKET, BY APPLICATION BY APPLICATION (USD MILLION) (2020–2027) 41

TABLE 29 UK BIOMARKER TESTS MARKET, BY END USERS (USD MILLION) (2020–2027) 41

TABLE 30 ITALY BIOMARKER TESTS MARKET, BY APPLICATION (USD MILLION) (2020–2027) 42

TABLE 31 ITALY BIOMARKER TESTS MARKET, BY END USERS (USD MILLION) (2020–2027) 42

TABLE 32 SPAIN BIOMARKER TESTS MARKET, BY APPLICATION (USD MILLION) (2020–2027) 43

TABLE 33 SPAIN BIOMARKER TESTS MARKET, BY END USERS (USD MILLION) (2020–2027) 43

TABLE 34 REST OF EUROPE BIOMARKER TESTS MARKET, BY APPLICATION (USD MILLION) (2020–2027) 44

TABLE 35 REST OF EUROPE BIOMARKER TESTS MARKET, BY END USERS (USD MILLION) (2020–2027) 44

TABLE 36 ASIA-PACIFIC BIOMARKER TESTS MARKET BY, COUNTRY (USD MILLION) (2020–2027) 45

TABLE 37 ASIA-PACIFIC BIOMARKER TESTS MARKET, BY APPLICATION (USD MILLION) (2020–2027) 46

TABLE 38 ASIA-PACIFIC BIOMARKER TESTS MARKET, BY END USERS (USD MILLION) (2020–2027) 46

TABLE 39 JAPAN BIOMARKER TESTS MARKET, BY APPLICATION (USD MILLION) (2020–2027) 47

TABLE 40 JAPAN BIOMARKER TESTS MARKET, BY END USERS (USD MILLION) (2020–2027) 47

TABLE 41 CHINA BIOMARKER TESTS MARKET, BY APPLICATION (USD MILLION) (2020–2027) 48

TABLE 42 CHINA BIOMARKER TESTS MARKET, BY END USERS (USD MILLION) (2020–2027) 48

TABLE 43 INDIA BIOMARKER TESTS MARKET, BY APPLICATION (USD MILLION) (2020–2027) 49

TABLE 44 INDIA BIOMARKER TESTS MARKET, BY END USERS (USD MILLION) (2020–2027) 49

TABLE 45 SOUTH KOREA BIOMARKER TESTS MARKET, BY APPLICATION (USD MILLION) (2020–2027) 50

TABLE 46 SOUTH KOREA BIOMARKER TESTS MARKET, BY END USERS (USD MILLION) (2020–2027) 50

TABLE 47 AUSTRALIA BIOMARKER TESTS MARKET, BY APPLICATION (USD MILLION) (2020–2027) 51

TABLE 48 AUSTRALIA BIOMARKER TESTS MARKET, BY END USERS (USD MILLION) (2020–2027) 51

TABLE 49 REST OF ASIA-PACIFIC BIOMARKER TESTS MARKET, BY APPLICATION (USD MILLION) (2020–2027) 52

TABLE 50 REST OF ASIA-PACIFIC BIOMARKER TESTS MARKET, BY END USERS (USD MILLION) (2020–2027) 52

TABLE 51 MIDDLE EAST & AFRICA BIOMARKER TESTS MARKET BY, COUNTRY (USD MILLION) (2020–2027) 53

TABLE 52 MIDDLE EAST & AFRICA BIOMARKER TESTS MARKET, BY APPLICATION (USD MILLION) (2020–2027) 54

TABLE 53 MIDDLE EAST & AFRICA BIOMARKER TESTS MARKET, BY END USER (USD MILLION) (2020–2027) 54

TABLE 54 UAE BIOMARKER TESTS MARKET, BY APPLICATION (USD MILLION) (2020–2027) 55

TABLE 55 UAE BIOMARKER TESTS MARKET, BY END USER (USD MILLION) (2020–2027) 55

TABLE 56 SAUDI ARABIA BIOMARKER TESTS MARKET, BY APPLICATION (USD MILLION) (2020–2027) 56

TABLE 57 SAUDI ARABIA BIOMARKER TESTS MARKET, BY END USER (USD MILLION) (2020–2027) 56

TABLE 58 EGYPT BIOMARKER TESTS MARKET, BY APPLICATION (USD MILLION) (2020–2027) 57

TABLE 59 EGYPT BIOMARKER TESTS MARKET, BY END USERS (USD MILLION) (2020–2027) 57

TABLE 60 REST OF MIDDLE & AFRICA BIOMARKER TESTS MARKET, BY APPLICATION (USD MILLION) (2020–2027) 58

TABLE 61 REST OF MIDDLE & AFRICA BIOMARKER TESTS MARKET, BY END USERS (USD MILLION) (2020–2027) 58

TABLE 62 GE HEALTHCARE: KEY DEVELOPMENT 73

TABLE 63 MEDTRONICS: KEY DEVELOPMENT 76

12 List Of Figures

FIGURE 1 REGULATORY PATHWAY OPTION FOR DIAGNOSTICS 12

FIGURE 2 RESEARCH PROCESS 15

FIGURE 3 GLOBAL BIOMARKER TESTS MARKET, BY APPLICATION (USD MILLION) (2020–2027) 25

FIGURE 4 GLOBAL BIOMARKER TESTS MARKET, BY END USERS (USD MILLION) (2020–2027) 29

FIGURE 5 GLOBAL BIOMARKER TESTS MARKET, BY REGION (USD MILLION) (2020–2027) 32

FIGURE 6 NORTH AMERICA BIOMARKER TESTS MARKET, BY COUNTRY MARKET SHARE 2018 (%) 33

FIGURE 7 EUROPE BIOMARKER TESTS MARKET, BY COUNTRY MARKET SHARE 2018 (%) 37

FIGURE 8 ASIA-PACIFIC BIOMARKER TESTS MARKET BY, COUNTRY MARKET SHARE 2018 (%) 45

FIGURE 9 MIDDLE EAST & AFRICA BIOMARKER TESTS MARKET BY, COUNTRY MARKET SHARE 2018 (%) 53

FIGURE 10 GLOBAL BIOMARKER TEST COMPETITIVE ANALYSIS (%) 59

FIGURE 11 F. HOFFMANN-LA ROCHE AG: FINANCIAL REVENUE 61

FIGURE 12 F. HOFFMANN-LA ROCHE AG: SEGMENTAL REVENUE 61

FIGURE 13 NOVARTIS FINANCIAL DATA: REVENUE AND R&D 64

FIGURE 14 NOVARTIS FINANCIAL DATA: SEGMENTAL REVENUE 64

FIGURE 15 NOVARTIS FINANCIAL DATA: GEOGRAPHICAL REVENUE 64

FIGURE 16 PFIZER FINANCIAL DATA: REVENUE AND R&D 66

FIGURE 17 PFIZER FINANCIAL DATA SEGMENTAL REVENUE 67

FIGURE 18 PFIZER FINANCIAL DATA GEOGRAPHICAL REVENUE 67

FIGURE 19 GLOAXOSMITHKLINE: RECENT FINANCIAL 69

FIGURE 20 GLAXOSMITHKLINE: OPERATING SEGMENTS 70

FIGURE 21 GLAXOSMITHKLINE: GEOGRAPHICAL MIX 70

FIGURE 22 GE HEALTHCARE: RECENT FINANCIAL 72

FIGURE 23 GE HEALTHCARE: OPERATING SEGMENTS 73

FIGURE 24 GE HEALTHCARE: GEOGRAPHICAL MIX 73

FIGURE 25 MEDTRONICS: RECENT FINANCIAL 75

FIGURE 26 MEDTRONICS: OPERATING SEGMENTS 76

FIGURE 27 MEDTRONICS: GEOGRAPHICAL MIX 76

FIGURE 28 QUEST DIAGNOSTICS: OPERATING INCOME 78

FIGURE 29 QUEST DIAGNOSTICS: SEGMENTAL REVENUE 79